We spoke to Andrew Doig, professor of biochemistry at the University of Manchester, to find out more about the evolving landscape of Alzheimer's treatments.
Swissmedic is expected to decide on the approval of the first new drug for Alzheimer’s disease in two decades. The decision ...
One in four people are left to cope alone after a diagnosis with dementia, research has found. The study by The Alzheimer’s ...
An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...
Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
Memory Treatment Centers to Study Brain Volume Changes in Alzheimer's Patients on Anti-Amyloid Drugs
The Florida-based provider will work with AI software company AiraMed to analyze and measure patients' brain volume from MRIs.
Annovis Bio saw promising results for Buntanetap in treating Alzheimer's and Parkinson's, but short cash runway prompts a ...
A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...
An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...
In the US, the FDA approved a new Alzheimer's treatment in July 2024 called donanemab. The treatment is for people with early symptomatic Alzheimer's disease, including mild cognitive impairment and ...
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback